NeuroReform Holdings, LLC
PrivateLast Round
Seed Round
Apr 13, 2026
Momentum
Top 25%
of companies Caplight tracks
Company Overview
NeuroReform Holdings, LLC is a medical technology company that developed the NeuroReformer®, an FDA-cleared device using AI-calibrated neurofrequencies to restore nerve and muscle function for rehabilitation.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Sports & Fitness, Medical AI
Business Model
B2B
Customer Profile
Hardware + Subscription, Services & Consulting, Usage-Based SaaS, Freemium
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeuroReform Holdings, LLC Comparables
Compare NeuroReform Holdings, LLC with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neuvotion, Inc. | 83% | |
| Bioventus | 74% | |
| MYOLYN, Inc. | 71% | |
NeuroReform Holdings, LLC Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Apr 13, 2026 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 13, 2026
$150K Seed Round completed.
NeuroReform Holdings, LLC Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about NeuroReform Holdings, LLC's valuation, stock price, and market status.